An inflammation of the colon associated with C. difficile — C. difficile colitis — has increased nearly 50 percent from 2001-2005 to 2006-2010, according to a study in the Journal of the American ...

NEW YORK (MedscapeWire) Mar 12 — Fulminant colitis with Clostridium difficile is becoming more common and more fatal, according to a review of hospitalized patients reported in the March issue of ...

Most patients suffering from C difficile colitis can be treated with antibiotic therapy, but up to 10% of patients eventually require colectomy. The authors proposed a less aggressive surgical ...

A new Phase 2 pilot study shows that giving spores of a non-toxic C. difficile bacteria by mouth is effective in stopping repeated bouts of C. diff infection, a major complication of hospitalization.

Clostridium difficile infections elevate the risks for colectomy, mortality and postoperative complications after a colectomy for patients with ulcerative colitis, according to NEJM Journal Watch.

Background: Clostridium difficile infections are becoming more common, more severe, and more likely to recur. Conventional treatment with antibiotics often fails to eradicate the infection; even when ...

Q: I'm not sure you'll take this question because of the subject matter, but it seems pretty important. Our dad had a fecal transplant as a last-ditch treatment for C. diff (Clostridioides difficile), ...

Fifteen isolates of Clostridium difficile from hamsters and human patients were inhibited or killed by low concentrations of metronidazole, vancomycin, penicillin, and ampicillin; the isolates were ...

Researchers used a harmless amoeba to safeguard children from dangerous colitis (C. difficile) infections, revealed a study. The Hartwell Foundation which supports early-stage, cutting-edge biomedical ...

The epidemiology of colitis induced by Clostridium difficile in hamsters was studied with a new bacteriophage and bacteriocin typing system. Fatal enterocolitis was induced by administration of ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced the presentation of its final 24-week data from the pivotal Phase 3 ...